Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $164,400.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider directly owned 1,222,312 shares of the company’s stock, valued at $20,094,809.28. This trade represents a 0.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Adaptive Biotechnologies Trading Down 1.3%

Shares of Adaptive Biotechnologies stock opened at $15.76 on Friday. The stock’s fifty day simple moving average is $16.45 and its 200 day simple moving average is $14.31. The company has a market capitalization of $2.41 billion, a PE ratio of -29.18 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 12 month low of $5.97 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company’s revenue for the quarter was up 102.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.22) earnings per share. Analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $793,000. SG Americas Securities LLC increased its holdings in Adaptive Biotechnologies by 53.2% during the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock worth $435,000 after buying an additional 12,963 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new position in Adaptive Biotechnologies during the second quarter worth $6,618,000. Diversified Trust Co bought a new stake in Adaptive Biotechnologies during the second quarter worth $438,000. Finally, Envestnet Asset Management Inc. acquired a new stake in Adaptive Biotechnologies in the second quarter valued at $467,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average price target of $17.11.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.